Biogen Pharmachem Industries Ltd (BIOGEN) Share Price & Fundamentals

What we do

Biogen Pharmachem Industries Ltd is engaged in trading shares, securities, commodities including agro-based and precious metals, with a recent shift towards pharmaceuticals since 2021.

Founded in

1,995

Market share

Nascent; limited trading operations with potential growth in pharmaceuticals sector.

Problem solved

Addresses trading market demands in commodities and securities, diversifying into pharmaceutical ingredients.

Top clients or who we serve

Serves traders and commodity market participants; future focus may include pharmaceutical clients.

Key management

Kelash Bunkar (Chairman and Whole-Time Director & CFO), Ms. Aman Pravin Kumar Patel (Independent Director).

Our journey and innovations

Founded in 1995, the company transformed from commodity trading to pharmaceuticals in 2021; exploring wind power previously.

Where we operate

India, mainly Rajkot region; no indication of export markets.

Top products or what we offer

Trading in shares, securities, agro and precious metal commodities; pharmaceutical ingredients post 2021.

Top brands

-

Raw materials needed

Precious metals like gold and silver; pharmaceutical raw materials post business shift.

Raw materials supplier

-

Recurring vs cyclical contribution

Mostly cyclical revenue from trading activities; no confirmed recurring revenue yet.

Our industry position

Small scale player with limited market presence; transitioning towards pharmaceuticals for growth.

Financial highlights

Revenue Rs. 1.2 crore, Net loss Rs. 0.29 crore for FY2024-25 with no dividend declared.

Geographical revenue split

-

Order book

-

Whats driving growth

Business diversification into pharmaceuticals and trading commodities.

Our future plans

Expanding pharmaceutical business; no significant capital investments reported yet.

Our green promise

-

Our people and values

Small employee base; focus on transparency and governance; zero tolerance for workplace harassment.

Key challenges ahead

Financial consolidation, market competition, regulatory compliance, and business diversification risks.

Interesting facts

Company changed name twice, latest shift to pharmaceutical sector from trading in 2021.

Risks and strategy

Risks include market volatility and regulatory compliance; strategy focuses on diversification and governance.